LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth

Oncogene

Volumn 30, Issue 16, 2011, Pages 1892-1900

  Zhou, J ^a   Yang, Z ^b   Tsuji, T ^c   Gong, J ^a   Xie, J ^a   Chen, C ^c   Li, W ^a   Amar, S ^d   Luo, Z ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHAANXI NORMAL UNIVERSITY   (China)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON UNIVERSITY   (United States)

Author keywords

AMPK; LITAF; p53; TNFSF15; tumor suppressor; tumorigenesis

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; AMP ACTIVATED KINASE ALPHA 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPOPOLYSACCHARIDE INDUCED TUMOR NECROSIS FACTOR ALPHA FACTOR; SHORT HAIRPIN RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME BINDING; ENZYME SUBUNIT; GENE SILENCING; IN VITRO STUDY; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR VOLUME; UPREGULATION;

ADENYLATE KINASE; ENZYME ACTIVATION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15;

BOVINAE;

EID: 79955463156     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.575     Document Type: Article

References (33)

1. Bayry J. (2010). Immunology: TL1A in the inflammatory network in autoimmune diseases. Nat Rev Rheumatol 6: 67-68.
2. Beauvais K, Furby A, Latour P. (2006). Clinical, electrophysiological and molecular genetic studies in a family with X-linked dominant Charcot-Marie-Tooth neuropathy presenting a novel mutation in GJB1 promoter and a rare polymorphism in LITAF/SIMPLE. Neuromuscul Disord 16: 14-18. (Pubitemid 43089621)
3. Bennett CL, Shirk AJ, Huynh HM, Street VA, Nelis E, Van Maldergem L et al. (2004). SIMPLE mutation in demyelinating neuropathy and distribution in sciatic nerve. Ann Neurol 55: 713-720. (Pubitemid 38544332)
4. Chang JY, He RY, Lin HP, Hsu LJ, Lai FJ, Hong Q et al. (2010). Signaling from membrane receptors to tumor suppressor WW domain-containing oxidoreductase. Exp Biol Med (Maywood) 235: 796-804.
5. Hardie DG. (2007). AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785. (Pubitemid 47462132)
6. Haridas V, Shrivastava A, Su J, Yu GL, Ni J, Liu D et al. (1999). VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth. Oncogene 18: 6496-6504.
7. Hong YH, Lillehoj HS, Lee SH, Park DW, Lillehoj EP. (2006). Molecular cloning and characterization of chicken lipopolysacchar-ide-induced TNF-alpha factor (LITAF). Dev Comp Immunol 30: 919-929. (Pubitemid 44066571)
8. Hou W, Medynski D, Wu S, Lin X, Li LY. (2005). VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. Clin Cancer Res 11: 5595-5602. (Pubitemid 41060838)
9. Latour P, Gonnaud PM, Ollagnon E, Chan V, Perelman S, Stojkovic T et al. (2006). SIMPLE mutation analysis in dominant demyelinat-ing Charcot-Marie-Tooth disease: three novel mutations. J Peripher Nerv Syst 11: 148-155. (Pubitemid 43894082)
10. Ludes-Meyers JH, Kil H, Bednarek AK, Drake J, Bedford MT, Aldaz CM. (2004). WWOX binds the specific proline-rich ligand PPXY: identification of candidate interacting proteins. Oncogene 23: 5049-5055. (Pubitemid 38938738)
11. Luo Z, Zang M, Guo W. (2010). AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 6: 457-470.
12. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R, Climent J, Fresquet V et al. (2007). Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood 109: 271-280. (Pubitemid 46053067)
13. Myokai F, Takashiba S, Lebo R, Amar S. (1999). A novel lipopolysaccharide-induced transcription factor regulating tumor necrosis factor alpha gene expression: molecular cloning, sequencing, characterization, and chromosomal assignment. Proc Natl Acad Sci USA 96: 4518-4523. (Pubitemid 29190368)
14. Nelson JD, Denisenko O, Bomsztyk K. (2006). Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc 1: 179-185.
15. Niemann A, Berger P, Suter U. (2006). Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease. Neuromol Med 8: 217-242.
16. Pan X, Wang Y, Zhang M, Pan W, Qi ZT, Cao GW. (2004). Effects of endostatin-vascular endothelial growth inhibitor chimeric recombi-nant adenoviruses on antiangiogenesis. World J Gastroenterol 10: 1409-1414. (Pubitemid 39206801)
17. Parr C, Gan CH, Watkins G, Jiang WG. (2006). Reduced vascular endothelial growth inhibitor (VEGI) expression is associated with poor prognosis in breast cancer patients. Angiogenesis 9: 73-81. (Pubitemid 44440552)
18. Picornell Y, Mei L, Taylor K, Yang H, Targan SR, Rotter JI. (2007). TNFSF15 is an ethnic-specific IBD gene. Inflamm Bowel Dis 13: 1333-1338. (Pubitemid 350206842)
19. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. (1997). A model for p53-induced apoptosis. Nature 389: 300-305. (Pubitemid 27406646)
20. Sethi G, Sung B, Aggarwal BB. (2009). Therapeutic potential of VEGI/TL1A in autoimmunity and cancer. Adv Exp Med Biol 647: 207-215.
21. Stucchi A, Reed K, O'Brien M, Cerda S, Andrews C, Gower A et al. (2006). A new transcription factor that regulates TNF-alpha gene expression, LITAF, is increased in intestinal tissues from patients with CD and UC. Inflamm Bowel Dis 12: 581-587. (Pubitemid 43977739)
22. Tang X, Fenton MJ, Amar S. (2003). Identification and functional characterization of a novel binding site on TNF-alpha promoter. Proc Natl Acad Sci USA 100: 4096-4101. (Pubitemid 36418163)
23. Tang X, Marciano DL, Leeman SE, Amar S. (2005). LPS induces the interaction of a transcription factor, LPS-induced TNF-alpha factor, and STAT6(B) with effects on multiple cytokines. Proc Natl Acad Sci USA 102: 5132-5137.
24. Tang X, Metzger D, Leeman S, Amar S. (2006). LPS-induced TNF-alpha factor (LITAF)-deficient mice express reduced LPS-induced cytokine: evidence for LITAF-dependent LPS signaling pathways. Proc Natl Acad Sci USA 103: 13777-13782. (Pubitemid 44413984)
25. Tang X, Molina M, Amar S. (2007). p53 short peptide (p53pep164) regulates lipopolysaccharide-induced tumor necrosis factor-b/cytokine expression. Cancer Res 67: 1308-1316.
26. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z. (2004). AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321: 161-167. (Pubitemid 39055618)
27. Xiang X, Zang M, Waelde CA, Wen R, Luo Z. (2002). Phosphoryla-tion of 338SSYY341 regulates specific interaction between Raf-1 and MEK1. J Biol Chem 277: 44996-45003. (Pubitemid 36159098)
28. Young HA, Tovey MG. (2006). TL1A: a mediator of gut inflammation. Proc Natl Acad Sci USA 103: 8303-8304. (Pubitemid 43838448)
29. Yue TL, Ni J, Romanic AM, Gu JL, Keller P, Wang C et al. (1999). TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. J Biol Chem 274: 1479-1486.
30. Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C et al. (1999a). VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 13: 181-189. (Pubitemid 29038287)
31. Zhai Y, Yu J, Iruela-Arispe L, Huang WQ, Wang Z, Hayes AJ et al. (1999b). Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 82: 131-136. (Pubitemid 29266118)
32. Zhang BB, Zhou G, Li C. (2009). AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 9: 407-416.
33. Zhou J, Huang W, Tao R, Ibaragi S, Lan F, Ido Y et al. (2009). Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells. Oncogene 28: 1993-2002.